Worth Venture Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Worth Venture Partners’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-657,885	Closed	-$1.67M	–	205
2023 Q1	$1.67M	Sell	657,885 -364,590	-36%	-$720K	0.82%	34
2022 Q4	$1.91M	Buy	1,022,475 +52,777	+5%	+$132K	1.13%	29
2022 Q3	$2.49M	Hold	969,698	–	–	1.53%	20
2022 Q2	$2.37M	Buy	969,698 +185,967	+24%	+$406K	1.39%	23
2022 Q1	$2.33M	Buy	783,731 +226,899	+41%	+$854K	1.08%	34
2021 Q4	$2.5M	Buy	556,832 +167,392	+43%	+$794K	1.24%	29
2021 Q3	$1.89M	Buy	389,440 +158,068	+68%	+$871K	0.85%	41
2021 Q2	$1.58M	Buy	231,372 +40,279	+21%	+$326K	0.59%	50
2021 Q1	$1.35M	Hold	191,093	–	–	0.65%	46
2020 Q4	$1.2M	Buy	191,093 +18,556	+11%	+$109K	0.95%	31
2020 Q3	$933K	Buy	+172,537	New	+$854K	0.77%	33
2017 Q2	–	Sell	-31,676	Closed	-$609K	–	159
2017 Q1	$609K	Buy	31,676 +28,736	+977%	+$453K	0.54%	38
2016 Q4	$45K	Buy	+2,940	New	+$38.2K	0.05%	103

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Worth Venture Partners's PRTK Position: Q2 2023 in Review

Worth Venture Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 657,885 shares — an estimated $1.67M sold.

Worth Venture Partners first reported a position in PRTK in Q4 2016 and held it in 13 quarters. The position peaked at $2.5M in Q4 2021. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Worth Venture Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Worth Venture Partners sold 657,885 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $1.67M.
Worth Venture Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 13 quarters.
Worth Venture Partners's Paratek Pharmaceuticals, Inc. position peaked at $2.5M in Q4 2021.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.